Trial · NCT05211050
Effect of Sumatriptan on Levcromakalim-Induced Symptoms in Individuals With Migraine
NCT05211050, Not applicable, Completed, Danish Headache Center
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of Sumatriptan on Levcromakalim-Induced Symptoms in Individuals With Migraine. Trials, record NCT05211050. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05211050
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of Sumatriptan on Levcromakalim-Induced Symptoms in Individuals With Migraine
- NCT number
- NCT05211050
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 24 participants, actual
- Lead sponsor
- Danish Headache Center
- Conditions
- Migraine Without Aura, Headache
- Interventions
- Levcromakalim, Sumatriptan, Saline
- First posted
- 2022-01-27
- Last updated
- 2025-01-22
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of migraine attacks | Assessed from baseline to 12 hours after infusion of levcromakalim. | A migraine attack is defined as an attack fulfilling either (i) or (ii): (i) Headache fulfilling criteria C and D for migraine without aura according to the International Classification of Headache Disorders 3rd edition: C. Headache has at least two of the following characteristics: * unilateral location * pulsating quality * moderate or severe pain intensity (moderate to severe pain intensity is considered ≥4 on the numerical rating scale) * aggravation by cough (in-hospital phase) or causing avoidance of routine physical activity (out-hospital phase) D. During headache at least one of the following: * nausea and/or vomiting * photophobia and phonophobia (ii) Headache described as mimicking the patient's usual migraine attack and treated with acute migraine medication (rescue medication). |
| Secondary | Incidence of headache | Assessed from baseline to 12 hours after infusion of levcromakalim. | Incidence of headache is defined as headache intensity ≥1 as measured by a numerical rating scale (NRS) from 0 to 10. It is a verbally declared scale from 0 to 10, where 0 is no pain and 10 is the worst pain imaginable. |
| Secondary | Intensity of headache | Assessed from baseline to 12 hours after infusion of levcromakalim. | Headache intensity scores are measured by a numerical rating scale (NRS). It is a verbally declared scale from 0 to 10, where 0 is no pain and 10 is the worst pain imaginable. |
| Secondary | Diameter of superficial temporal artery (STA) assessed using high frequency ultrasound | Assessed from baseline to 2 hours after infusion of levcromakalim. | Diameter (mm) of superficial temporal artery (STA) is measured as a continuous outcome using high frequency ultrasound (Dermascan C, Cortex Technology, Denmark). |
| Secondary | Incidence of adverse events | Assessed from baseline to 12 hours after infusion of levcromakalim. | Participants are instructed to inform the investigators in the case of adverse events. |
| Other | Incidence of facial flushing | Assessed from baseline to 2 hours after infusion of levcromakalim. | Incidence of facial skin flushing assessed by the investigator as a binary outcome. |
| Other | Facial blood flow assessed using Laser Doppler Flowmetry | Assessed from baseline to 2 hours after infusion of levcromakalim. | Facial blood flow is measured as a continuous outcome using Laser Doppler Flowmetry (LDI, Moor Instruments, Devon, United Kingdom). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 40624944 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05211050
GET https://conductscience.org/api/trials/v1/NCT05211050/registered